Product Theater The Role of Antipsychotic TDM in Clinical Decision Making: The Example of Clozapine Supported by Saladax
Activity Date: 04/25/2022
Session Time and Location
The live session is complete.
Readily available therapeutic drug monitoring (TDM) of antipsychotic blood levels can provide evidenced-based and personalized psychopharmacologic treatment. Clozapine is the only evidence-based antipsychotic option for treatment resistant schizophrenia and schizophrenia patients with suicidality, with a wealth of data on plasma level response thresholds and the point of futility. For medications such as clozapine, patients and healthcare providers have many situations where TDM is highly relevant in making day-to-day clinical decisions, including differentiating poor adherence with ultrarapid metabolism, and optimizing levels in inadequate responders. During this session, the faculty will discuss the unique place of clozapine for treatment resistant schizophrenia, and the role of TDM in clozapine dosing during titration, and for monitoring ongoing adherence. An open microphone session will follow the presentations.
Faculty Information and Disclosures
Jonathan Meyer, MD Rob Cotes, MD Deanna Kelly, PharmD, BCPP Megan Ehret, PharmD, MS, BCPP
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Rob Cotes has received research funding (to instituition) from Otsuka, Lunbeck, Roche and Alkermes. He is a consultant to Saladax Biomedical and the American Psychaitric Association.
Deanna Kelly serves as a consultant for Sunovian, Lyndra Therapeutics, and Alkermes. She has received compensation from Saladax Biomedical for presenting at CPNP.
Jonathan Meyer is a consultant to Acadia Pharmaceuticals, Alkermes, Allergan, Intra-Cellular Therapies, and Neurocrine, Noven Pharmaceuticals Inc., Otsuka America Inc., Sunovion Pharamceuticals, and Teva Pharmaceutical Industries. He has received compensation from Saladax Biomedicalfor presenting at CPNP.
Megan Ehret is a Lexi-Comp Consultant/Reviewer. She has received compensation from Saladax Biomedical for presenting at CPNP.
All relevant relationships have been mitigated.
Sponsored by Saladax Biomedical
By continuing to use the site, you agree to this collection.